Thoracic Malignancies

ASCO 2020

Questions discussed in this category

Should 3 years of adjuvant osimertinib be the standard of care for resected Stage IB-IIIA EGFRm NSCLC?

6 Answers available

Papers discussed in this category

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-12-01

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.

N Engl J Med, 2020 Sep 19

Osimertinib in Resected -Mutated Non-Small-Cell Lung Cancer.

J Clin Oncol, 2020 Dec 04

Lessons From ADAURA on Adjuvant Cancer Drug Trials: Evidence, Ethics, and Economics.

Related Topics in Thoracic Malignancies